Q&A: What Will It Take to Reshore US Drug Manufacturing?

Why It Matters

For operators, the issue points to the practical constraints behind moving pharmaceutical production back onshore, including capacity, compliance, labor, and supplier depth. For investors and supply chain leaders, reshoring drug manufacturing matters because it can shift capex needs, operating costs, and exposure to overseas disruption.